Partnership
CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market
CSL; VarmX; VMX-C001; blood clotting drug; Factor Xa inhibitors; anticoagulants; Phase 3 clinical trial; acquisition; biotech partnership; critical bleeding; FDA fast-track
Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program
Genentech; Roche; OMass Therapeutics; inflammatory bowel disease (IBD); preclinical program; biotech partnership; OdyssION platform; small molecule therapy; drug discovery; milestone payments
Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology
Novartis; BioArctic; BrainTransporter platform; blood-brain barrier; neurodegeneration; Leqembi; partnership; antibody; milestone payments; royalties
Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases
Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment
Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends
Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment
Imunon Halts COVID-19 Vaccine Program, Seeks Partner Due to Financial Struggles
Imunon; COVID-19 vaccine; IMNN-101; deprioritization; cash crunch; partnership; financial results
Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million
Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments
Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market
Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal
LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal
LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news
AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China
AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment